CA-RECOVER
7.7.2021 18:53:08 CEST | Business Wire | Press release
Three leading companies in the textiles industry, Recover™, Happy Punt, and Hansae, have entered into a multi-year partnership agreement to provide end-to-end solutions for the design, development, and production of sustainably conscious apparel for the fashion industry. The partnership allows retailers and brands to seamlessly integrate sustainable Recover™ recycled cotton fiber into their products, thereby helping to solve one of the world’s biggest environmental issues.
Using innovative technology, the partnership provides a range of services, including 3D design, patterns, tech packs, samples, and production to support brands and retailers at every step in the supply chain. The partnership offers a unique speed to market solution for the production of fully sustainable apparel and leverages the group’s global reach, with offices in Seoul, Barcelona, and New York. In addition, close customer proximity provides in-market technical design services that develop, review and approve all specifications to ensure correct fit and brand enhancing products.The partnership also provides an end-to-end service that combines the advantages of production nearshore and offshore worldwide.
Dedicated leading edge design and development facilities can produce samples in house from concept to finished sample with a quick turnaround time. Notably, as part of a joint sustainability initiative, the partnership also encourages R&D designs to be replaced by 3D designs to reduce the environmental impact of the sampling process.
The three leading companies have a combined experience of over 130 years in each of their respective fields. Each firm’s commitment to bringing the best technology to the product and the market offers a disruptive approach to the traditional apparel design and production process. The partnership is proud to be actively working with leading global brands to deliver sustainable collections to the market by Spring 2022, and more collections are expected to follow.
Recover™ will increase its production to 200,000 metric tons of recycled cotton fiber per year by 2025 to support the current market demand. This recycled cotton volume will save nearly three trillion liters of water each year, equivalent to the drinking water consumed by 3 billion people on an annual basis and allow 500,000 acres of land to be directed away from cotton cultivation to other uses.
The Recover™, Happy Punt, and Hansae strategic partnership provides brands and retailers with an easy plug & play solution to achieve their sustainability initiatives and ensures a quality product for the consumer.
About Recover™
Recover™ is a leading material sciences company and global producer of low-impact, high-quality recycled cotton fiber and cotton fiber blends. Its premium, environmentally friendly, and cost-competitive products are created in partnership with the supply chain for global retailers and brands, offering a sustainable solution to achieve circular fashion for all.
As a fourth-generation, family-owned company with over a 70-year history in the textile industry, Recover™ is on a mission to scale its proprietary technology to make a lasting positive impact on the environment and partner with brands/retailers and other change-makers to meet the industry’s sustainability targets.
For more information, visit www.recovertex.com and follow @recoverfiber on social media.
About Happy Punt
Happy Punt is a design and manufacturing end-to-end solution provider to the fashion industry, applying virtual design tools supported by the best technology offering an efficient and sustainable product development and design process. Founded in 1996, Happy Punt has more than 25 years of history in the fashion business, and a team of 80 fashion designers and PD&D. Happy Punt offers a “Gold Standard” of excellence in technical and production know-how that ensures the manufacturing and delivery of safe and reliable products by providing a global end-to-end service recognized for the quality of their fashion design and for the speed of their creative process.
About Hansae
Established in 1982, Hansae Co., Ltd. has maintained consistent growth through specialized apparel exports and annually produces over 300 million garments. Hansae has 14 global corporations in 7 countries, over 600 people at the corporate Headquarters, and over 35,000 in the global manufacturing workforce.
Its mission is to enrich customer’s lives and lead fashion culture by providing the best quality clothes at a reasonable price. Quality management systems maximize values for its customers by ensuring manufacturing excellence and on-time, safe delivery of products.
Hansae has developed HAMS, its own smart factory system to maximize the efficiency of production plants in Vietnam, Indonesia, Myanmar, Nicaragua, Guatemala, and Haiti.
Hansae aims to be a front-runner in sustainable management by establishing ‘10% For Good’, pledging to donate 10 percent of its net profits from sustainable orders to third parties that work toward improving ocean environment by collecting wastes, the advancement of green raw materials, and hardware upgrades and retrofits.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210707005776/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom